Aclaris Therapeutics (ACRS) Other Non-Current Assets (2014 - 2026)

Aclaris Therapeutics' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 24.85% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 24.85% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 9.62% from the prior year.
• Other Non-Current Assets eased to $2.4 million in Q1 2026 per ACRS's latest filing, from $2.8 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $4.2 million in Q4 2023 and bottomed at $2.4 million in Q1 2026.
• The 5-year median for Other Non-Current Assets is $3.1 million (2024), against an average of $3.1 million.
• Across the five-year window, Other Non-Current Assets soared 52.2% in 2023 and decreased 26.26% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $2.7 million in 2022, then soared by 52.2% to $4.2 million in 2023, then dropped by 26.26% to $3.1 million in 2024, then decreased by 9.62% to $2.8 million in 2025, then slipped by 14.54% to $2.4 million in 2026.
• Per Business Quant, the three latest ACRS Other Non-Current Assets figures stand at $2.4 million (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025).